Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | OTC | P00480 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | BHMT | Q93088 | 1/20 | 0.38 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1768365 | 1.00 | NOS2 (0.44) | NOS2NOS3NOS1OTCDNM1 | |
| SCHEMBL1768709 | 0.90 | NOS2 (0.42) | NOS2NOS3NOS1OTCDNM1 | |
| SCHEMBL1768704 | 0.90 | NOS2 (0.42) | NOS2NOS3NOS1OTCDNM1 | |
| SCHEMBL13584744 | 0.87 | DNM1 (0.41) | NOS2NOS3NOS1DNM1HPGD | |
| SCHEMBL13584740 | 0.87 | DNM1 (0.41) | NOS2NOS3NOS1DNM1HPGD | |
| SCHEMBL1769569 | 0.83 | DNM1 (0.54) | NOS2NOS3NOS1OTCDNM1 | |
| SCHEMBL1769572 | 0.83 | DNM1 (0.54) | NOS2NOS3NOS1OTCDNM1 | |
| SCHEMBL1768810 | 0.81 | NOS2 (0.49) | NOS2NOS3NOS1OTCGSR | |
| SCHEMBL1768808 | 0.81 | NOS2 (0.45) | NOS2NOS3NOS1OTCDNM1 | |
| SCHEMBL1768812 | 0.81 | NOS2 (0.45) | NOS2NOS3NOS1OTCDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| EP-2501715-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | Polyphor Ag (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011060937-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | CCR10, CCR1, CCRL2 | NOS2 4664/4885NOS3 4757/4885NOS1 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.